Mastering API Solid Forms: A Deep Dive into Polymorphism, Crystallization, and Characterization

Understanding API Solid Forms

APIs can exist in several solid forms, each with unique physicochemical characteristics.

• Polymorphs: Polymorphs are defined as the capability of a compound to exist in two or more crystalline forms, characterized by variations in molecular arrangements (packing polymorphism) and/or conformations (conformational polymorphism) within the crystal lattice. In essence, polymorphs share the same chemical composition but differ in their lattice structures and/or molecular conformations. This phenomenon is prevalent, with over half of all active pharmaceutical ingredients exhibiting polymorphism. To date, only a few medicinally active substances, such as aspirin, can be regarded as non-polymorphic in a practical sense. However, it remains theoretically possible that these non-polymorphic organic compounds could have potential polymorphs. This difference in molecular packing leads to variations in physical properties such as melting point, density, hardness, intrinsic dissolution rate, and spectroscopic characteristics.
• Solvates and Hydrates: Solvates are crystalline forms that incorporate solvent molecules into their crystal lattice. When the solvent is water, the form is specifically called a hydrate. These forms can have distinct properties from their anhydrous or non-solvated counterparts. For instance, a hydrate might be less soluble than the anhydrous form due to the strong interactions between the API and water molecules in the crystal structure.
• Salts: Salts are crystalline forms created by an acid-base reaction between an ionizable API and a counterion. This process transforms the API into an ionic compound, which can significantly alter its physicochemical properties, particularly solubility and dissolution rate. For instance, a weakly acidic API might be formulated as a sodium salt to increase its aqueous solubility, while a basic API might be converted into a hydrochloride salt for the same reason. Salt formation is a common strategy in drug development to improve bioavailability and enhance drug product stability.
• Co-Crystals: Co-crystals are multi-component solid forms consisting of an API and one or more neutral co-former molecules, bound together through non-covalent interactions (e.g., hydrogen bonding, π-π stacking, van der Waals forces) in a crystal lattice. Unlike salts, co-crystals do not involve proton transfer. Co-crystallization offers a powerful approach to modify the physical properties of an API without altering its chemical structure. This can lead to improved solubility, dissolution rate, physical stability, and even taste masking. For example, a poorly soluble API can be co-crystallized with a GRAS (Generally Recognized As Safe) co-former to enhance its bioavailability. Co-crystals present an exciting avenue for patent protection and life cycle management of existing drugs.
• Amorphous Forms: In contrast to crystalline forms, amorphous forms lack a long-range ordered crystal lattice. They are characterized by a disordered arrangement of molecules, similar to a supercooled liquid. Amorphous forms typically exhibit higher apparent solubility and faster dissolution rates compared to their crystalline counterparts due to their higher free energy. However, they are also thermodynamically less stable and prone to converting to more stable crystalline forms over time, which can lead to product instability and performance variability. Amorphous solid dispersions, where an API is dispersed in a polymer matrix, are a common strategy to stabilize amorphous forms and enhance bioavailability.

Fig. 1. Several solid forms of APIs.

Crystallization: Controlling API Solid Forms

Crystallization is a critical unit operation in pharmaceutical manufacturing, determining the final solid form of the API. Effective crystallization design and control are essential to consistently produce the desired polymorph, hydrate, solvate, salt, or co-crystal with the required purity and physical properties. Key factors include:

• Nucleation and Crystal Growth: Crystallization involves two main stages: nucleation (the formation of initial crystal nuclei) and crystal growth (the enlargement of these nuclei). Controlling these processes by manipulating parameters like supersaturation, temperature, cooling rate, stirring speed, and solvent composition is key to influencing the polymorphic outcome. For instance, rapid cooling or high supersaturation can favor the formation of less stable, kinetic polymorphs or amorphous forms, while slower cooling and lower supersaturation might lead to more stable, thermodynamic polymorphs, salts, or co-crystals.
• Solvent Selection: Solvent selection is perhaps the most crucial factor in polymorph, salt, and co-crystal control. Different solvents can stabilize different solid forms by interacting uniquely with the API molecules (and co-formers/counterions) during crystallization. Co-solvents and anti-solvents are also frequently used to fine-tune supersaturation and influence the crystallization pathway.
• Seed Crystals: The use of seed crystals of a desired polymorph, salt, or co-crystal can effectively direct crystallization towards that specific form, even if it's not the thermodynamically most stable form under the given conditions. Seeding promotes heterogeneous nucleation, bypassing the need for spontaneous nucleation of potentially undesirable forms.
• Temperature and Cooling Profiles: Precise control of temperature and cooling profiles during crystallization is essential. Controlled cooling rates can influence crystal size distribution and minimize the formation of impurities or undesired solid forms. Isothermal crystallization or temperature cycling can also be employed to achieve specific polymorphic outcomes.
• Impurities: The presence of impurities can significantly affect nucleation and crystal growth, potentially inhibiting or promoting the formation of specific polymorphs, salts, or co-crystals. Understanding impurity profiles and their impact on crystallization is vital.

Related Services from Our Company

API Solid State Research and Development

• Salt Screening
• Co-Crystal Screening
• Polymorph Screening
• Amorphous Solid Dispersion Screening
• Crystallization Process Development and Optimization

Techniques: Characterization for API Solid Forms

Robust characterization of API solid forms is essential throughout drug development. Various analytical techniques are employed to identify, quantify, and understand the properties of different solid forms.

• X-ray Powder Diffraction (XRPD): XRPD is the most widely used technique for characterizing crystalline solid forms. It provides a unique "fingerprint" for each crystalline phase based on its crystal lattice. By analyzing the diffraction pattern (peak positions and intensities), one can identify different polymorphs, solvates, hydrates, salts, and co-crystals, and assess the crystallinity of a sample. XRPD is also quantitative, allowing for the determination of the percentage of different crystalline phases in a mixture.
• Differential Scanning Calorimetry (DSC): DSC measures the heat flow associated with transitions in a material as a function of temperature. It's invaluable for identifying melting points, glass transition temperatures (for amorphous materials), and solid-solid phase transformations. Each polymorph, salt, or co-crystal typically has a distinct melting point, making DSC a powerful tool for solid form screening and identification. It can also detect desolvation events for solvates and hydrates.
• Thermogravimetric Analysis (TGA): TGA measures the change in weight of a sample as it's heated. This technique is particularly useful for identifying and quantifying the presence of solvates and hydrates by monitoring weight loss due to solvent evaporation.
• Fourier-Transform Infrared (FT-IR) Spectroscopy and Raman Spectroscopy: FT-IR spectroscopy and Raman spectroscopy provide information about the vibrational modes of molecules. Since different crystal packing arrangements can lead to subtle changes in molecular conformation and intermolecular interactions, these techniques can often differentiate between polymorphs, solvates, hydrates, salts, and co-crystals. They are non-destructive and can be used for in-line process monitoring.
• Solid-State Nuclear Magnetic Resonance (ssNMR) Spectroscopy: ssNMR spectroscopy offers detailed information about the local molecular environment and long-range order within the solid state. It is a powerful tool for elucidating crystal structures, confirming polymorphism, and identifying intermolecular interactions. For salts and co-crystals, ssNMR can provide direct evidence of the ionic or non-covalent interactions present in the lattice. While more complex than other techniques, ssNMR provides unique structural insights.
• Dynamic Vapor Sorption (DVS): DVS measures the amount of moisture adsorbed or desorbed by a sample as a function of relative humidity. This technique is crucial for understanding the hygroscopicity of APIs and for identifying hydrate formation or deliquescence. Different solid forms can exhibit varying moisture uptake characteristics.
• Scanning Electron Microscopy (SEM): SEM provides high-resolution images of particle morphology and size. While not directly identifying polymorphism, SEM can reveal differences in crystal habit and surface characteristics between different solid forms, which can impact downstream processing such as flowability and compaction.

Our Services

At our company, we are a leading provider of comprehensive services in polymorphism and crystallization for APIs. Leveraging our state-of-the-art analytical facilities and a team of experienced solid-state scientists, we offer tailored solutions to address the challenges of API solid forms throughout the drug development lifecycle. Our services include:

• Polymorph Screening and Identification: We conduct thorough polymorph screens using a variety of solvents, temperatures, and crystallization techniques to identify all relevant solid forms of your API. Our robust characterization suite (XRPD, DSC, TGA, FT-IR, Raman, ssNMR) ensures accurate identification and differentiation of polymorphs, solvates, and hydrates.
• Salt Screening and Co-Crystal Screening: We perform systematic salt and co-crystal screens to explore additional solid forms that can improve physicochemical properties such as solubility, stability, and manufacturability. We meticulously characterize these forms to identify the most promising candidates.
• Amorphous Form Generation and Stabilization: For APIs with poor solubility, we develop strategies for generating and stabilizing amorphous forms, including amorphous solid dispersions, and provide characterization of their stability and dissolution properties.
• Crystallization Process Development and Optimization: Our team designs and optimizes crystallization processes to consistently yield the desired solid form (polymorph, salt, co-crystal, etc.) with high purity and optimal particle properties. We employ a data-driven approach, utilizing process analytical technology (PAT) to monitor and control critical process parameters.
• Solid Form Stability Studies: We assess the physical and chemical stability of API solid forms under various stress conditions (temperature, humidity, light) to determine their long-term stability and inform storage conditions and shelf-life.

By partnering with us, you gain access to unparalleled expertise and advanced technologies that can significantly de-risk your drug development pipeline, accelerate time to market, and ensure the consistent quality and performance of your API. We are committed to providing innovative solutions that empower our clients to overcome complex solid-state challenges in pharmaceutical development.

Please kindly note that our services are for research use only.